Egypt Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Egypt Pharmaceuticals and Healthcare Report Q3 2013 Jun 19th 2013, 00:00 BMI View: While BMI’s core view for Egypt is that it will eventually emerge from its political turmoil as a stronger economy with a greater emphasis on healthcare, there are obvious downside risks to this view. The biggest threats to the country’s pharmaceuticals and healthcare industry are the drug pricing regime - which is disadvantaging local production with unprofitable margins – the political uncertainty and the loss of foreign investment and tourism, which bodes poorly for its macroeconomic growth. Headline Expenditure Projections ?? Pharmaceuticals: EGP12.83bn (US$2.11bn) in 2012 to EGP14.45bn (US$2.01bn) in 2013; +12.6% in local currency terms and -5.0% … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=103162. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/egypt-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions